Open AccessEffects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
Author(s) -
S. Verma,
D.K. McGuire,
S.C. Bain,
D.L. Bhatt,
L.A. Leiter,
C.D. Mazer,
T. Monk Fries,
R.E. Pratley,
S. Rasmussen,
H. Vrazic,
B. Zinman,
J.B. Buse
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/n642-gk64
Subject(s) - semaglutide , liraglutide , medicine , body mass index , type 2 diabetes , glucagon like peptide 1 , endocrinology , glucagon like peptide 1 receptor , diabetes mellitus , receptor , agonist